ArticleInfluenza and other respiratory viruses2021
Using serological measures to estimate influenza incidence in the presence of secular trends in exposure and immuno-modulation of antibody response.
Article in Influenza and other respiratory viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 13 citations in OpenAlex.
- Use of anti-nucleocapsid antibody detection as a marker of SARS-CoV-2 infection in healthcare professionals: a longitudinal seroprevalence study at a university hospital in Catalonia, Spain.BMC infectious diseases · 2026Article
- Serodynamics: A primer and synthetic review of methods for epidemiological inference using serological data.Epidemics · 2024Review
- Reconstructed influenza A/H3N2 infection histories reveal variation in incidence and antibody dynamics over the life course.PLoS biology · 2024Article
- Reconstructed influenza A/H3N2 infection histories reveal variation in incidence and antibody dynamics over the life course.medRxiv : the preprint server for health sciences · 2024Article
- Article
- Observational
- Reconstructing antibody dynamics to estimate the risk of influenza virus infection.Nature communications · 2022Article
- Using serological measures to estimate influenza incidence in the presence of secular trends in exposure and immuno-modulation of antibody response.Influenza and other respiratory viruses · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 4 countries.
Funding
Abstract
backgroundInfluenza infection is often measured by a fourfold antibody titer increase over an influenza season (ie seroconversion). However, this approach may fail when influenza seasons are less distinct as it does not account for transient effects from recent infections. Here, we present a method to determine seroconversion for non-paired sera, adjusting for changes in individuals' antibody titers to influenza due to the transient impact of recent exposures, varied sampling times, and laboratory processes.
methodsWe applied our method using data for five H3N2 strains collected from 942 individuals, aged 2-90 years, during the first two study visits of the Fluscape cohort study (2009-2012) in Guangzhou, China.
resultsAfter adjustment, apparent seroconversion rates for non-circulating strains decreased while we observed a 20% increase in seroconversion rates to recently circulating strains. When examining seroconversion to the most recently circulating strain (A/Brisbane/20/2007) in our study, participants aged under 18, and over 64 had the highest seroconversion rates compared to other age groups.
conclusionsOur results highlight the need for improved methods when using antibody titers as an endpoint in settings where there is no clear influenza "off" season. Methods, like those presented here, that use titers from circulating and non-circulating strains may be key.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.